We’re thrilled to back Octozi, an agentic AI platform transforming clinical data cleaning, review, and reconciliation.
Octozi’s AI platform automates processes involved in data cleaning and review, decreasing the time needed for database lock while enhancing data quality. Their models are trained on clinical and drug-specific data to detect discrepancies and manage and prioritize data queries. The platform also generates Patient Profiles, Serious Adverse Event Narratives, and data visualizations to support medical monitors, clinical scientists, and data managers. By centralizing data from various trial systems, Octozi eliminates data silos and enables collaboration across study teams. In one recent study, Octozi demonstrated the potential to accelerate processes by 4x.
Excited to partner with Octozi, tackling one of Debiopharm and pharma’s core pain points: inefficient, manual data cleaning in clinical trials. This investment builds on internal initiatives to modernize clinical workflows.
Cedric Odje, Investment Associate at Debiopharm Innovation Fund
We’re excited to partner with Debiopharm to accelerate Octozi’s mission of transforming clinical development with AI. Their deep expertise in oncology and rare diseases, combined with their role as a forward-thinking innovator, makes them an ideal partner as we scale. This collaboration not only helps accelerate adoption of Octozi’s platform in these high-impact therapeutic areas, but will also help us to better meet the needs of the growing number of pharma companies we work with to modernize clinical data workflows.
Amit Patel, CEO of Octozi